JPRN-C000000416已完成3 期
Randomized study of Taxane vs TS-1 in metastatic or recurrent breast cancer patients - Selection of effective chemotherapy for breast cancer (SELECT BC)
SELECT BC executive committee0 个研究点目标入组 600 人开始时间: 2006年6月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)During pregnancy or lactation, or planning to get pregnant 2)HER2(Her2/neu, Erb B2) IHC (3+) or FISH(fluorescence in situ hybridization) (+) at primary or metastatic lesion 3)Anaphylaxis against medicine or solvent of this protocol treatment 4)Active double cancers 5)Brain metastasis which needs treatment for hyperfunction of intracranial pressure or urgent irradiation 6)Extended liver metastasis or lymphatic lung metastasis with dyspnea 7)Only one assessable lesion having past radiation therapy 8)Retention of pleural fluid, ascites and pericardial fluid which need urgent treatment 9)Active infectious disease 10)Interstitial pneumonia or idiopathic interstitial pneumonia 11)HBs(+) 12)Diabetes mellitus in bad control or during insulin treatment 13)Mental disease with difficulty of taking part in this study 14)Patients judged inappropriate for this study by the physicians
研究者
相似试验
进行中（未招募）
1 期
A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer - COMPLETEHER2/ErbB2 positive metastatic breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2007-004568-27-DEovartis Pharma Services AG600
进行中（未招募）
不适用
A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer - COMPLETEHER2/ErbB2 positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-004568-27-BEGlaxoSmithKline Research and Development Ltd600
进行中（未招募）
1 期
A comparison of the efficacy of Lapatinib vs. Trastuzumab, when each is given with a Taxane (either Paclitaxel or Docetaxel) in the treatment of first line metastatic breast cancer.EUCTR2007-004568-27-GBovartis Pharma Services AG600
进行中（未招募）
不适用
A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer - COMPLETE:HER2/ErbB2 positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-004568-27-NLGlaxoSmithKline Research and Development Ltd600
进行中（未招募）
1 期
A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer ['COMPLETE' study: Comparison of Lapatinib Efficacy vs. Trastuzumab, Each with a Taxane in First Line Metastatic Breast Cancer] - COMPLETE (see under A.3 Full title of the trial)HER2/ErbB2 positive metastatic breast cancerMedDRA version: 9.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancerEUCTR2007-004568-27-FRGlaxoSmithKline Research and Development Ltd600